Literature DB >> 31319742

Advances in the prediction of long-term effectiveness of immune checkpoint blockers for non-small-cell lung cancer.

Sara Elena Rebuzzi1,2, Alessandro Leonetti1, Marcello Tiseo1,3, Francesco Facchinetti4.   

Abstract

Entities:  

Keywords:  advanced non-small-cell lung cancer; anti-PD-1; anti-PD-L1; immune-checkpoint inhibitors; immunotherapy; long-term outcomes

Mesh：

Substances：

Year:  2019        PMID： 31319742     DOI： 10.2217/imt-2019-0107

Source DB:  PubMed          Journal:  Immunotherapy        ISSN： 1750-743X            Impact factor:   4.196


× No keyword cloud information.
  7 in total

Review 1.  Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non-small Cell Lung Cancer.

Authors:  Giuseppe Lo Russo; Francesco Facchinetti; Marcello Tiseo; Marina Chiara Garassino; Roberto Ferrara
Journal:  Curr Oncol Rep       Date:  2020-04-16       Impact factor: 5.075

2.  [Advances in Hyperprogressive Disease in Patients 
with Advanced Non-small Cell Lung Cancer Treated with Immunotherapy].

Authors:  Shuyang Yao; Kejian Shi; Yi Zhang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2021-04-20

3.  Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis.

Authors:  Giorgia Guaitoli; Marcello Tiseo; Massimo Di Maio; Luc Friboulet; Francesco Facchinetti
Journal:  Transl Lung Cancer Res       Date:  2021-06

4.  PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors.

Authors:  Foteinos-Ioannis Dimitrakopoulos; Achilleas Nikolakopoulos; Anastasia Kottorou; Fotini Kalofonou; Elias Liolis; Theodora Frantzi; Ioannis Pyrousis; Angelos Koutras; Thomas Makatsoris; Haralabos Kalofonos
Journal:  Cancers (Basel)       Date:  2020-05-16       Impact factor: 6.639

Review 5.  Immunotherapy in patients with non-small cell lung cancer with ECOG PS 2.

Authors:  Damian Mojsak; Beata Kuklińska; Michał Dębczyński; Robert Marek Mróz
Journal:  Contemp Oncol (Pozn)       Date:  2021-04-06

6.  Three models that predict the efficacy of immunotherapy in Chinese patients with advanced non-small cell lung cancer.

Authors:  Qian Zhao; Butuo Li; Yiyue Xu; Shijiang Wang; Bing Zou; Jinming Yu; Linlin Wang
Journal:  Cancer Med       Date:  2021-08-13       Impact factor: 4.452

7.  Validation of Patras Immunotherapy Score model for prediction and prognosis of patients with advanced NSCLC treated with nivolumab or pembrolizumab: results from a European multicentre study.

Authors:  Foteinos-Ioannis Dimitrakopoulos; Giannis Mountzios; Petros Christopoulos; Thomas Papastergiou; Mariam Elshiaty; Lea Daniello; Elefterios Zervas; Sofia Agelaki; Epaminondas Samantas; Adamantia Nikolaidi; Ilias Athanasiadis; Sofia Baka; Konstantinos Syrigos; Athina Christopoulou; Evangelos Lianos; Konstantinos Samitas; Nikolaos Tsoukalas; Eleni-Isidora Perdikouri; George Oikonomopoulos; Anastasia Kottorou; Foteini Kalofonou; Thomas Makatsoris; Angelos Koutras; Vasileios Megalooikonomou; Haralabos Kalofonos
Journal:  Ther Adv Med Oncol       Date:  2022-09-08       Impact factor: 5.485
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.